Talon Drops on FDA Review of Cancer Therapy: San Francisco MoverSamantha Zee
Talon Therapeutics Inc. fell the most since November 2010 after the U.S. Food and Drug Administration said it wants more time to review information about Talon’s Marqibo blood-cancer treatment.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Ivanka Trump Faces Courtroom Showdown Over $785 Sandals
- Uber Losing Battle in London After Regulator Revokes License
- How Electric Cars Can Create the Biggest Disruption Since the iPhone
- Mercedes Plots Tesla Attack With $1 Billion U.S. Electric Push
- Hewlett Packard Enterprise Is Said to Plan About 5,000 Job Cuts